Summary

• User fee program key to funding for FDA’s drug reviews
• Talks between FDA, pharma industry for program renewal in 2027 due to begin FDA job cuts include 15 staff preparing for those talks
• Cuts mean FDA risks handing industry upper hand in talks-expert